Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,108 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,001)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07038343 | AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | recruiting | Phase 1 / Phase 2 | 480 | Avenzo Therapeutics, Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07062055 | BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases | recruiting | Phase 2 | 54 | Shandong Cancer Hospital and InstituteOTHER | 1 | Sep 4, 2026 |
| clinicaltrials |
| NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | recruiting | Phase 1 | 540 | PfizerINDUSTRY | 6 | Sep 4, 2026 | clinicaltrials |
| NCT07360119 | Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors | recruiting | N/A | 20 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07416552 | A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 1 | 180 | Hoffmann-La RocheINDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07661641 | A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors | recruiting | Phase 1 | 115 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07803770 | EUS-Based Artificial Intelligence to Predict Outcomes in Pancreatic Cancer(EUS-AI-R) | not yet recruiting | — | 700 | IRCCS San RaffaeleOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07803783 | A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic Chemotherapy | not yet recruiting | Phase 3 | 320 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07805551 | A Study of HDM2017 Combination Therapy in Advanced Colorectal Cancer | recruiting | Phase 1 / Phase 2 | 220 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07805681 | Observational Registry Evaluating the Clinical Impact of the Blood-Based Biomarker Test for Early-Stage Pancreatic Ductal Adenocarcinoma(ASSURE) | not yet recruiting | — | 400 | Immunovia, Inc.INDUSTRY | 0 | Sep 4, 2026 | clinicaltrials |
| NCT03460769 | Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) | active not recruiting | — | 775 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04069273 | Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma(SEQUEL) | active not recruiting | Phase 2 | 58 | Harry H YoonOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04524871 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)(MORPHEUS-LIVER) | active not recruiting | Phase 1 / Phase 2 | 518 | Hoffmann-La RocheINDUSTRY | 7 | Sep 3, 2026 | clinicaltrials |
| NCT04967183 | Polyprev: Study to Compare Fecal Immunochemical Test With Endoscopic Surveillance After Advanced Adenoma Resection in Fecal Immunochemical Test Colorectal Cancer Screening Programs. | active not recruiting | N/A | 3,788 | Fundacin Biomedica Galicia SurOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05141643 | Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer | active not recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT05673148 | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial | recruiting | Phase 2 | 146 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT05677490 | mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | recruiting | Phase 3 | 382 | Alliance for Clinical Trials in OncologyOTHER | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06252649 | Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation(CodeBreaK 301) | recruiting | Phase 3 | 450 | AmgenINDUSTRY | 35 | Sep 3, 2026 | clinicaltrials |
| NCT06337084 | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06445972 | Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | recruiting | Phase 1 / Phase 2 | 210 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 3, 2026 | clinicaltrials |
| NCT06617169 | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors | active not recruiting | Phase 1 | 12 | Monopar TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06811116 | Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial | recruiting | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06921785 | Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma(ARTEMIDE-HCC01) | recruiting | Phase 3 | 1,220 | AstraZenecaINDUSTRY | 20 | Sep 3, 2026 | clinicaltrials |
| NCT06999837 | [68Ga]Ga-PSMA PET/CT in Hepatocellular Carcinoma: Impact of Multiparametric Dynamic Whole-body Imaging and Kinetic Modeling.(HIMIKO) | recruiting | N/A | 40 | Nantes University HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07120295 | Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories | recruiting | Phase 4 | 75 | University of Colorado, DenverOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07418164 | Endoscopic Management of Biliopancreatic Disease in the Lombardy Pancreas Units(GENTLENESS) | not yet recruiting | — | 2,500 | IRCCS San RaffaeleOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07446257 | THIO and Cadonilimab in Resectable Hepatocellular Carcinoma | recruiting | Early Phase 1 | 60 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07602842 | A Study of IDP-001 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | InduPro, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07644559 | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer | recruiting | Phase 2 | 180 | Verastem, Inc.INDUSTRY | 3 | Sep 3, 2026 | clinicaltrials |
| NCT07650773 | CHARM Hepatocellular Carcinoma MEA Study | recruiting | — | 4,000 | AstraZenecaINDUSTRY | 7 | Sep 3, 2026 | clinicaltrials |
| NCT07801027 | A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) | not yet recruiting | Phase 4 | 150 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 3, 2026 | clinicaltrials |
| NCT07801287 | Iparomlimab/Tuvonralimab Plus SBRT and Lenvatinib for Perioperative Treatment of Potentially Resectable Intermediate-Stage HCC | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801352 | CapeOx Combined With Anti-PD1 Antibody Plus Dihydroartemisinin as Neoadjuvant or Conversion Therapy for Microsatellite Stable Locally Advanced and Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802184 | GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDAC | not yet recruiting | Phase 1 / Phase 2 | 45 | West China HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802197 | Neoadjuvant Radiotherapy vs Upfront Surgery in Locally Advanced Proximal Rectal Cancer(PRELUDE) | recruiting | N/A | 100 | Istanbul UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802418 | Molecularly Tailored Therapy in Advanced Pancreatic Cancer(TAILOR-PANC) | not yet recruiting | Phase 2 | 1,200 | Herlev HospitalOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07803159 | Frailty, Immunonutrition, Surgery Type, and Biologic Recovery in Elderly Gastric Cancer | not yet recruiting | — | 328 | Kocaeli City HospitalOTHER_GOV | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03440450 | A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer | active not recruiting | Phase 1 | 90 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04188535 | Serial MRI Scans During Radiation Therapy(RELAY) | recruiting | N/A | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04611867 | Study of PRO in Patients With Advanced Pancreatic or Biliary Tract Cancer (BetterEveryDay)(BetterEveryDay) | recruiting | N/A | 274 | Inna Chen, MDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04749108 | Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma(GRECCAR14) | recruiting | Phase 2 / Phase 3 | 1,075 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04803201 | Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma | recruiting | Phase 2 | 170 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05080673 | Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps(FORTE) | recruiting | N/A | 9,500 | NRG OncologyOTHER | 2 | Sep 2, 2026 | clinicaltrials |
| NCT05174169 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease(CIRCULATE-US) | recruiting | Phase 2 / Phase 3 | 1,912 | NRG OncologyOTHER | 3 | Sep 2, 2026 | clinicaltrials |
| NCT05245500 | Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 336 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05247905 | Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors, the ComPareNET Trial | active not recruiting | Phase 2 | 31 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05286814 | PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma | recruiting | Phase 2 | 70 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05319730 | A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | recruiting | Phase 1 / Phase 2 | 230 | Merck Sharp & Dohme LLCINDUSTRY | 14 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Sep 4, 2026source: clinicaltrials